The present application provides a medicinal product comprising: an the HER2 inhibitor or a CDK inhibitor, wherein said CDK inhibitor inhibits CDK4 and/or CDK6. The present application also provides an the HER2 inhibitor for the use of treating tumor in combination with a CDK inhibitor, as well as their use in the preparation of a medicament for treating tumor. The combination in present will significantly enhance tumor inhibiting.

Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Described herein are methods of treating a cancer, for example, a hematologic malignancy or a solid tumor, in a patient in need thereof, comprising administering to the patient a Bcl-2 inhibitor in combination with a second anti-cancer agent.

Disclosed are means of enhancing therapeutic activities of fibroblasts through manipulation of nuclear receptor activation accomplished by, intra alia, alteration in hormone levels. In some embodiments angiogenic, and/or neurogenic, and/or immunomodulatory activities of fibroblasts are increased by normalization or augmentation of sex-specific hormones. In one embodiment a candidate for fibroblast therapy is administered hormones, pro-hormones, or growth factors to augment therapeutic activities of fibroblasts. In some embodiments fibroblasts are treated in vitro prior to administration with various hormones and/or growth factors in order to augment therapeutic activities of said cells.

Disclosed are means of enhancing therapeutic activities of fibroblasts through manipulation of nuclear receptor activation accomplished by, intra alia, alteration in hormone levels. In some embodiments angiogenic, and/or neurogenic, and/or immunomodulatory activities of fibroblasts are increased by normalization or augmentation of sex-specific hormones. In one embodiment a candidate for fibroblast therapy is administered hormones, pro-hormones, or growth factors to augment therapeutic activities of fibroblasts. In some embodiments fibroblasts are treated in vitro prior to administration with various hormones and/or growth factors in order to augment therapeutic activities of said cells.

The present invention discloses a system and method for increasing the lifespan and quality of life of human beings and other mammals. This discloses methods for preparing and delivering various health and longevity compositions. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation, misting, nasal spray, suppository, etc. An existing compound known to have capacity for life extending potential, rapamycin, is combined with a non-toxic therapeutic anabolic hormone, e.g., DHEA, and cannabidiol (CBD) to enable absorption and effect. These three compounds work together to dramatically improve both the quality of life in aging humans and other mammals as well as extending the life of humans potentially up to 120 healthy years. One preferred embodiment provides a method for continuous low dose supplementation, e.g., incorporated in or with a daily meal. This invention not only resolves the issue of anti-aging of higher life forms, without toxicity, but provides for an improved method for absorption.

The present invention discloses a system and method for increasing the lifespan and quality of life of human beings and other mammals. This discloses methods for preparing and delivering various health and longevity compositions. The compositions of the present invention are selected and designed for the purpose of efficiently delivering health and longevity enhancing therapies through oral supplementation, misting, nasal spray, suppository, etc. An existing compound known to have capacity for life extending potential, rapamycin, is combined with a non-toxic therapeutic anabolic hormone, e.g., DHEA, and cannabidiol (CBD) to enable absorption and effect. These three compounds work together to dramatically improve both the quality of life in aging humans and other mammals as well as extending the life of humans potentially up to 120 healthy years. One preferred embodiment provides a method for continuous low dose supplementation, e.g., incorporated in or with a daily meal. This invention not only resolves the issue of anti-aging of higher life forms, without toxicity, but provides for an improved method for absorption.

Provided are methods and compositions for promoting cellular metabolism and cellular repair in a tissue of a subject in need thereof. The composition includes at least one N-methyl-D-aspartate receptor (NMDAR) modulator to modulate metabolic activity in cells and at least one nuclear factor erythroid 2-related factor 2 (NRF2) modulator to modulate repair activity in cells. Optionally, the composition also includes at least one inactive component and at last one microbial modulator. The composition synergistically modulates a positive-feedback signal-amplification cycle comprising NMDAR and NRF2 in cells, which, in turn, promotes cellular metabolic fitness (CMF) in a tissue of a subject in need thereof.

Provided are methods and compositions for promoting cellular metabolism and cellular repair in a tissue of a subject in need thereof. The composition includes at least one N-methyl-D-aspartate receptor (NMDAR) modulator to modulate metabolic activity in cells and at least one nuclear factor erythroid 2-related factor 2 (NRF2) modulator to modulate repair activity in cells. Optionally, the composition also includes at least one inactive component and at last one microbial modulator. The composition synergistically modulates a positive-feedback signal-amplification cycle comprising NMDAR and NRF2 in cells, which, in turn, promotes cellular metabolic fitness (CMF) in a tissue of a subject in need thereof.

An implantable and refillable device for delivering a drug compound is provided. The device comprises a reservoir within which the drug compound is capable of being retained, wherein the reservoir defines a first surface and a second surface opposing the first surface. A release structure comprising a hydrophobic polymer surrounds at least a portion of the reservoir. The release structure is in communication with the reservoir such that the drug compound can pass from the reservoir through the release structure. A septum is positioned adjacent to the first surface of the reservoir and a backing layer is positioned adjacent to the second surface of the reservoir.